NDANASALSPRAY, METERED
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
NASONEX 24HR ALLERGY (mometasone furoate) by PharmaIN is corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. Approved for allergic rhinitis, chronic rhinosinusitis with nasal polyps, nasal polyps. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASONEX 24HR ALLERGY is a metered nasal spray containing mometasone furoate, a topical corticosteroid approved for allergic rhinitis, chronic rhinosinusitis with nasal polyps, and nasal polyps. It works by inducing phospholipase A2 inhibitory proteins (lipocortins) that suppress the biosynthesis of inflammatory mediators like prostaglandins and leukotrienes. The 24-hour formulation offers extended symptom relief with a single daily dose.
Peak
Product is at peak commercial momentum post-2022 approval with moderate competitive pressure (30/100), suggesting active brand-building and field team expansion.
Mechanism of Action
corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…
Worked on NASONEX 24HR ALLERGY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.